Bristol-myers Squibb Compnay

Five Prime Therapeutics, Inc.

Penny E Phillips

Brian Wong

Katherine E Lewis

Kevin Hestir

Ernestine A Lee

David Bellovin

Emma Masteller

Julie Hambleton

Robert Sikorski

Janine Powers

Michael Carleton

Steven H Bernstein

Shivani Srivastava

Serena Kimi Perna

Dimple Pandya

James Cassidy

Suba Krishnan

Haiqing Wang

Ke Xu

Justine Kamilah Walker

Katy Lynn Simonsen

Zheng Yang

Paul Andrew Basciano

Li Zhu

Alexander Azrilevich

Provided herein are methods for treating cancer, comprising administering to a subject having cancer a therapeutically effective amount of an anti-GITR antibody alone or together with an anti-PD-1 or anti-PD-L1 antibody.

Treatment of cancer with anti-GITR agonist antibodies

The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

The disclosure is directed to methods of treating cancer in subjects with a combination of a monoclonal antibody and (R)-N-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide, or a salt thereof.

Compositions and methods of treating cancer

Growing community of inventors

Princeton, NJ, United States of America

Penny E Phillips